Table of Contents Author Guidelines Submit a Manuscript
Journal of Skin Cancer
Volume 2014, Article ID 439205, 10 pages
http://dx.doi.org/10.1155/2014/439205
Research Article

Melanoma Development and Progression Are Associated with Rad6 Upregulation and β-Catenin Relocation to the Cell Membrane

1Laboratory for Molecular Dermatology, Barbara Ann Karmanos Cancer Institute, 110 East Warren Avenue, Detroit, MI 48201, USA
2Department of Dermatology, School of Medicine, Wayne State University, Detroit, MI 48201, USA
3Center for Molecular Medicine and Genetics, School of Medicine, Wayne State University, Detroit, MI 48201, USA
4Pinkus Dermatopathology Laboratory, Monroe, MI 48162, USA
5Biostatistics, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA
6Department of Oncology, School of Medicine, Wayne State University, Detroit, MI 48201, USA
7Department of Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA
8Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA

Received 24 January 2014; Revised 2 April 2014; Accepted 15 April 2014; Published 6 May 2014

Academic Editor: Selma Ugurel

Copyright © 2014 Karli Rosner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Rimm, K. Caca, G. Hu, F. B. Harrison, and E. R. Fearon, “Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma,” American Journal of Pathology, vol. 154, no. 2, pp. 325–329, 1999. View at Google Scholar · View at Scopus
  2. C.-T. Yeh, C.-J. Yao, J.-L. Yan et al., “Apoptotic cell death and inhibition of Wnt/β-catenin signaling pathway in human colon cancer cells by an active fraction (hs7) from taiwanofungus camphoratus,” Evidence-based Complementary and Alternative Medicine, vol. 2011, Article ID 750230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Zulehner, M. Mikula, D. Schneller et al., “Nuclear β-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence,” American Journal of Pathology, vol. 176, no. 1, pp. 472–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Bellei, A. Pitisci, C. Catricalà, L. Larue, and M. Picardo, “Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: Implication in cell differentiation,” Pigment Cell and Melanoma Research, vol. 24, no. 2, pp. 309–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Larue and V. Delmas, “Secrets to developing Wnt-age melanoma revealed,” Pigment Cell and Melanoma Research, vol. 22, no. 5, pp. 520–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Yaguchi, Y. Goto, K. Kido et al., “Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells,” The Journal of Immunology, vol. 189, no. 5, pp. 2110–2117, 2012. View at Publisher · View at Google Scholar
  7. H. R. Widlund, M. A. Horstmann, E. Roydon Price et al., “β-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor,” Journal of Cell Biology, vol. 158, no. 6, pp. 1079–1087, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. C. C. Wong, E. S. F. Lo, K. C. Lee, J. K. C. Chan, and W. L. W. Hsiao, “Prognostic and diagnostic significance of β-catenin nuclear Immunostaining in colorectal cancer,” Clinical Cancer Research, vol. 10, no. 4, pp. 1401–1408, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kageshita, C. V. Hamby, T. Ishihara, K. Matsumoto, T. Saida, and T. Ono, “Loss of β-catenin expression associated with disease progression in malignant melanoma,” British Journal of Dermatology, vol. 145, no. 2, pp. 210–216, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Demunter, L. Libbrecht, H. Degreef, C. De Wolf-Peeters, and J. J. Van den Oord, “Loss of membranous expression β-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations,” Modern Pathology, vol. 15, no. 4, pp. 454–461, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. O. M. Lucero, D. W. Dawson, R. T. Moon, and A. J. Chien, “A re-evaluation of the “oncogenic” nature of Wnt/β-catenin signaling in melanoma and other cancers,” Current Oncology Reports, vol. 12, no. 5, pp. 314–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. B. E. G. Rothberg, A. J. Berger, A. M. Molinaro et al., “Melanoma prognostic model using tissue microarrays and genetic algorithms,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5772–5780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Arozarena, H. Bischof, D. Gilby, B. Belloni, R. Dummer, and C. Wellbrock, “In melanoma, beta-catenin is a suppressor of invasion,” Oncogene, vol. 30, no. 45, pp. 4531–4543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Chien, E. C. Moore, A. S. Lonsdorf et al., “Activated Wnt/β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 4, pp. 1193–1198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. P. V. Shekhar, A. Lyakhovich, D. W. Visscher, H. Heng, and N. Kondrat, “Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation,” Cancer Research, vol. 62, no. 7, pp. 2115–2124, 2002. View at Google Scholar · View at Scopus
  16. M. P. V. Shekhar, B. Gerard, R. J. Pauley, B. O. Williams, and L. Tait, “Rad6B is a positive regulator of β-catenin stabilization,” Cancer Research, vol. 68, no. 6, pp. 1741–1750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. M. P. V. Shekhar, L. Tait, and B. Gerard, “Essential role of T-cell factor/β-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells,” Molecular Cancer Research, vol. 4, no. 10, pp. 729–745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Gerard, L. Tait, P. Nangia-Makker, and M. P. V. Shekhar, “Rad6B acts downstream of Wnt signaling to stabilize β-catenin: implications for a novel Wnt/β-catenin target,” Journal of Molecular Signaling, vol. 6, article 6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. P. V. Shekhar, L. A. Biernat, N. Pernick, L. Tait, J. Abrams, and D. W. Visscher, “Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response,” Medical Oncology, vol. 27, no. 2, pp. 466–473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Dihlmann and M. Von Knebel Doeberitz, “Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics,” International Journal of Cancer, vol. 113, no. 4, pp. 515–524, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. G. M. Mælandsmo, R. Holm, J. M. Nesland, Ø. Fodstad, and V. A. Flørenes, “Reduced β-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma,” Clinical Cancer Research, vol. 9, no. 9, pp. 3383–3388, 2003. View at Google Scholar · View at Scopus
  22. I. M. Bachmann, O. Straume, H. E. Puntervoll, M. B. Kalvenes, and L. A. Akslen, “Importance of P-cadherin, β-catenin, and Wnt5a/Frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma,” Clinical Cancer Research, vol. 11, no. 24, pp. 8606–8614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Roth, J. M. Grant-Kels, A. B. Ackerman et al., “The histopathology of dysplastic nevi: continued controversy,” American Journal of Dermatopathology, vol. 13, no. 1, pp. 38–51, 1991. View at Google Scholar · View at Scopus
  24. A. Lyakhovich and M. P. V. Shekhar, “RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response,” Oncogene, vol. 23, no. 17, pp. 3097–3106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Rosner, D. R. Mehregan, D. Moussai, J. Abrams, G. Tromp, and D. A. Mehregan, “WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi,” Journal of Cutaneous Pathology, vol. 36, no. 10, pp. 1077–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Mineta, K. Miura, S. Takebayashi et al., “Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma,” Oral Oncology, vol. 36, no. 2, pp. 194–198, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. D. C. Whiteman, W. J. Pavan, and B. C. Bastian, “The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin,” Pigment Cell and Melanoma Research, vol. 24, no. 5, pp. 879–897, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Gerard, M. A. Sanders, D. W. Visscher, L. Tait, and M. P. Shekhar, “Lysine 394 is a novel RAD6B-induced ubiquitination site on beta-catenin,” Biochimica et Biophysica Acta, vol. 1823, no. 10, pp. 1686–1696, 2012. View at Publisher · View at Google Scholar
  29. T. Oyama, Y. Yamada, K. Hata et al., “Further upregulation of β-catenin/Tcf transcription is involved in the development of macroscopic tumors in the colon of ApcMin/+ mice,” Carcinogenesis, vol. 29, no. 3, pp. 666–672, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. Morin, A. B. Sparks, V. Korinek et al., “Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC,” Science, vol. 275, no. 5307, pp. 1787–1790, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Palacios and C. Gamallo, “Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas,” Cancer Research, vol. 58, no. 7, pp. 1344–1347, 1998. View at Google Scholar · View at Scopus
  32. T. Sinnberg, M. Menzel, D. Ewerth et al., “β-catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance,” PLoS ONE, vol. 6, no. 8, Article ID e23429, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Zhang, C. Morrissey, S. Sun et al., “Androgen receptor variants occur frequently in castration resistant prostate cancer metastases,” PLoS ONE, vol. 6, no. 11, Article ID e27970, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. C. G. J. M. Hilders, I. M. Munoz, Y. Nooyen, and G. J. Fleuren, “Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance,” Gynecologic Oncology, vol. 57, no. 3, pp. 366–375, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. D. S. A. Sanders, K. Blessing, G. A. R. Hassan, R. Bruton, J. R. Marsden, and J. Jankowski, “Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours,” Journal of Clinical Pathology, Molecular Pathology, vol. 52, no. 3, pp. 151–157, 1999. View at Google Scholar · View at Scopus
  36. R. Silye, A. J. Karayiannakis, K. N. Syrigos et al., “E-cadherin/catenin complex in benign and malignant melanocytic lesions.,” The Journal of Pathology, vol. 186, no. 4, pp. 350–355, 1998. View at Google Scholar
  37. S. Kuphal and A. K. Bosserhoff, “Phosphorylation of β-catenin results in lack of β-catenin signaling in melanoma,” International Journal of Oncology, vol. 39, no. 1, pp. 235–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. G. De Panfilis, D. Ferrari, S. Santoro et al., “Cytoplasmic β-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?” British Journal of Dermatology, vol. 160, no. 3, pp. 600–608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Pećina-Slaus, M. Zigmund, V. Kusec, T. N. Martić, M. Cacić, and M. Slaus, “E-cadherin and β-catenin expression patterns in malignant melanoma assessed by image analysis,” Journal of Cutaneous Pathology, vol. 34, no. 3, pp. 239–246, 2007. View at Google Scholar
  40. S. Kuphal, I. Poser, C. Jobin, C. Hellerbrand, and A. K. Bosserhoff, “Loss of E-cadherin leads to upregulation of NFκB activity in malignant melanoma,” Oncogene, vol. 23, no. 52, pp. 8509–8519, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Bernard, A. Fleming, A. Lacombe, V. R. Harley, and E. Vilain, “Wnt4 inhibits β-catenin/TCF signalling by redirecting β-catenin to the cell membrane,” Biology of the Cell, vol. 100, no. 3, pp. 167–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Kavakebi, B. Hausott, A. Tomasino, S. Ingorokva, and L. Klimaschewski, “The N-end rule ubiquitin-conjugating enzyme, HR6B, is up-regulated by nerve growth factor and required for neurite outgrowth,” Molecular and Cellular Neuroscience, vol. 29, no. 4, pp. 559–568, 2005. View at Publisher · View at Google Scholar · View at Scopus